Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 3,520,000 shares, an increase of 7.6% from the October 31st total of 3,270,000 shares. Based on an average trading volume of 452,200 shares, the short-interest ratio is currently 7.8 days.
In related news, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares of the company's stock, valued at $483,141.51. This trade represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total transaction of $71,499.12. Following the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at approximately $8,478,032.64. The trade was a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,840 shares of company stock worth $259,128. Corporate insiders own 8.50% of the company's stock.
Several hedge funds have recently modified their holdings of BCYC. Harbor Capital Advisors Inc. boosted its stake in shares of Bicycle Therapeutics by 27.2% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 55,289 shares of the company's stock worth $1,119,000 after acquiring an additional 11,809 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Bicycle Therapeutics by 0.6% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company's stock valued at $17,975,000 after buying an additional 4,976 shares in the last quarter. Pinnacle Associates Ltd. lifted its stake in Bicycle Therapeutics by 202.2% in the 2nd quarter. Pinnacle Associates Ltd. now owns 242,001 shares of the company's stock valued at $4,898,000 after buying an additional 161,911 shares in the last quarter. Natixis Advisors LLC purchased a new position in Bicycle Therapeutics in the 2nd quarter valued at about $261,000. Finally, TD Asset Management Inc lifted its stake in Bicycle Therapeutics by 76.7% in the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company's stock valued at $1,967,000 after buying an additional 42,200 shares in the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have recently issued reports on BCYC. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. B. Riley downgraded Bicycle Therapeutics from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $33.00 to $28.00 in a research report on Wednesday, August 7th. Oppenheimer reaffirmed an "outperform" rating and set a $48.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. JMP Securities reaffirmed a "market outperform" rating and set a $32.00 price target on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Finally, HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Bicycle Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $40.13.
View Our Latest Research Report on Bicycle Therapeutics
Shares of BCYC opened at $20.01 on Tuesday. The business's 50-day moving average is $23.42 and its two-hundred day moving average is $22.94. The company has a market capitalization of $951.48 million, a P/E ratio of -6.08 and a beta of 0.89. Bicycle Therapeutics has a fifty-two week low of $14.33 and a fifty-two week high of $28.67.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same period in the prior year, the company posted ($1.26) EPS. The company's revenue for the quarter was down 50.0% on a year-over-year basis. Analysts forecast that Bicycle Therapeutics will post -3.07 EPS for the current year.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.